Royalty Report: Drugs, Pharmaceuticals, Delivery – Collection: 6580

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Delivery
  • Therapeutic
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6580

License Grant
The Licensor and Licensee have a license agreement for the Licensor's CPE-215 with Testosterone formulation – Testim.  Testim was was launched in the U.S. in early 2003. The Licensor recently obtained patents that cover the application of testosterone with CPE-215 in the U.S. and in foreign countries that continue through 2023.
License Property
The Licensor's platform drug delivery technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through development of proprietary formulations with molecules such as CPE-215.

Testim® is a gel for testosterone replacement therapy, which is a formulation of our technology with testosterone.

IPSCIO Record ID: 6388

License Grant
The Licensor granted the Licensee a sole and exclusive, worldwide, royalty-bearing License under the Licensor's Patents and Technology relating to the preparation, purification, characterization, stabilization, processing, and formulation and/or use of a testosterone topical formulation containing CPE-215. CPE-215 is a patented drug delivery technology.
License Property
CPE-215 enhances the absorption of drugs across a variety of biological membranes including the skin, mouth, nose and eye. The technology can be adapted to products formulated as creams, ointments, gels, solutions, lotions, sprays or patches.
Field of Use
Use Patents shall mean any patent granted in the Territory for the use of the Product in a specific therapeutic indication.

The Licensee will have the right to subLicense the Products in the territory. In addition, Licensee shall have the exclusive right to enter into another License Agreement to acquire rights in the Licensor's Patents and Technology for the development of Combination Products, such right to expire upon the termination of this Agreement.

IPSCIO Record ID: 26195

License Grant
The Licensor entered into a Development and License Agreement with the Licensee, to develop a nasal spray delivery product composition containing a molecule used in the treatment of nocturia, a condition causing an individual to wake one or more times at night to urinate.

The Licensor granted the Licensee an exclusive, sublicensable, worldwide License under United States Patent No. 7,244,703 and foreign equivalents and the Licensor's proprietary CPE-215 drug delivery technology to conduct research activities related to the development of the Licensee's product and to make and sell the product. The Licensee granted the Licensor a non-exclusive License to its technology and patents rights to conduct initial formulation activities under the Agreement.

Field of Use
The rights granted apply to specialty pharmaceutical company in the business of research and development of pharmaceutical products utilizing our validated drug delivery platform technology.

IPSCIO Record ID: 230786

License Grant
Licensor grants to Licensee of the Netherlands and Licensees Affiliates an exclusive, even as to Licensor, license right, with the right to grant sublicenses, to use and exploit Licensor IP Rights to import, market, sell and distribute the Product, in the Territory, in the Field.

Licensor also grants to Licensee the right to file Marketing Authorization Applications outside EU countries and to seek pricing and reimbursement approvals where required.

Licensor also grants to Licensee an exclusive, license right, with the right to grant sublicenses, to use the Trademark on and solely in connection with the commercialization of the Product throughout the Territory, in the Field.

License Property
Product means a pharmaceutical composition containing testosterone as the single active drug ingredient and CPE 215 which fall within the scope of any composition, method or claim of Licensor IP Rights and which is intended to be applied topically, including TESTIM 1% testosterone gel.

Trademark means TESTIM.

Field of Use
Field means the use of Product for testosterone replacement therapy to restore serum testosterone in adult males with primary and secondary hypogonadism or such equivalent or similar indication as authorized on a country-by-country basis, and any additional indications based on the existing dossier which do not require extra development work (to the exclusion of regulatory work); such additional indications, if initiated by Licensee, are subject to approval by Licensor.

Competing Product means all transdermal products containing testosterone as an active ingredient used for testosterone replacement therapy to restore serum testosterone in adult males with primary and secondary hypogonadism or such equivalent or similar indication.

IPSCIO Record ID: 63694

License Grant
As part of the termination, the Company reacquired the rights to the intellectual property.  All obligations under the prior license agreement have been completed except for a perpetual royalty on net sales for LPCN 1021.
License Property
LPCN 1021 An Oral Product Candidate for Testosterone Replacement Therapy

LPCN 1021 is an oral formulation of the chemical testosterone undecanoate (TU), an eleven carbon side chain attached to testosterone. TU is an ester prodrug of testosterone. An ester is chemically formed by bonding an acid and an alcohol. Upon the cleavage, or breaking, of the ester bond, testosterone is formed. TU has been approved for use outside the United States for many years for delivery via intra-muscular injection and in oral dosage form and TU has received regulatory approval in the United States for delivery via intra-muscular injection. We are using our Lip’ral technology to facilitate steady gastrointestinal solubilization and absorption of TU for twice daily oral dosing of TU.

Field of Use
This agreement pertains to the drug industry relating to testosterone.

IPSCIO Record ID: 239793

License Grant
The Parties entered the original agreement to undertake development of products containing the Compound which meet criteria set forth in the Research Agreement for commercialization in the Territory.

This amendment is made  to provide incentives to Licensee to enter into sublicenses for the Products in territories outside the United States; and to provide incentives to Licensee to extend the commercial life of the Products licensed under the License Agreement.

License Property
The compound is a dihydrotestosterone formulation which contains CPE-215.

Products means any and all pharmaceutical compositions which contain dihydrotestosterone as the single active drug ingredient; and, the Compound; and which fall within the scope of any composition, method or article claim of the Licensor Patents.

Field of Use
The purpose is for the use of the Product in a specific therapeutic indication.

Product relates to permeation facilitator, CPE-215, to develop topical gel formulations of testosterone.

IPSCIO Record ID: 27099

License Grant
The Swiss Company has granted Licensee an exclusive license, with the right to grant sublicenses for the licensing of E2/T Combi-Gel.E2/T Combi-Gel covers four hormone products for the treatment of hormone deficiencies in men and women.
License Property
Patents
5,891,462 – A Novel Composition for transdermal administration of an Estrogen, a Progestin or a mixture thereof (Combi Gel)
08/058,517 – Administration System for Estradiol (Estradiol Patch)

Products
Gel E2 (where Estradiol is the sole active ingredient, and where the gel is applied to the skin) Gel Testosterone (where testosterone is the sole active ingredient and where the gel is applied to the skin)
Patch E2 (where Estradiol is the sole active ingredient and where the patch is applied to the skin)
E2-**** Combi Gel (where Estradiol and *********** are the two active ingredients and where the gel is applied to the skin)
Option regarding E2-T Combi gel
E2-T Combi Gel (where Estradiol and Testosterone are the two active ingredients and where the gel is applied to the skin)

Field of Use
The rights granted apply to the Products which shall mean the four pharmaceutical products either dermal gel or patch, for application on the skin, intended for pharmaceutical use with humans for any indication now known or known in the future, and with defined active compounds.

IPSCIO Record ID: 4414

License Grant
The Swiss Company has granted Licensee an exclusive license, with the right to grant sublicenses for the licensing of E2/T Combi-Gel.E2/T Combi-Gel covers four hormone products for the treatment of hormone deficiencies in men and women.

This modification of the royalties does not apply for the products Estradiol single gel, Testosterone single gel and the combination product Estradiol plus Testosteron” but only and exclusive for E2-NETA Combi Gel.

License Property
Patents
5,891,462 – A Novel Composition for transdermal administration of an Estrogen, a Progestin or a mixture thereof (Combi Gel)
08/058,517 – Administration System for Estradiol (Estradiol Patch)

Products
Gel E2 where estradiol is the sole active ingredient, and where the gel is applied to the skin Gel Testosterone where testosterone is the sole active ingredient and where the gel is applied to the skin
Patch E2 where estradiol is the sole active ingredient and where the patch is applied to the skin
E2-**** Combi Gel where estradiol and *********** are the two active ingredients and where the gel is applied to the skin
Option regarding E2-T Combi gel
E2-T Combi Gel where Estradiol and Testosterone are the two active ingredients and where the gel is applied to the skin

Products shall mean the four pharmaceutical products either dermal gel or patch, for application on the skin, intended for pharmaceutical use with humans for any indication now known or known in the future, and with defined active compounds.

IPSCIO Record ID: 28250

License Grant
In May 2015, the Licensee acquired from the Licensor the approved new drug application for the previously-Licensed testerone gel product. Pursuant to the terms of the purchase Agreement, upon commercialization, the Licensee will pay a royalty as a result of commercial sale of the product.
License Property
The Licensor's Testosterone gel is an androgen indicated for replacement therapy in males for conditions associated with deficiency or absence of endogenous testosterone including primary hypogonadism and hypogonadotropic hypogonadism.
Field of Use
The Licensee acquired a testosterone gel product for commercialization.

IPSCIO Record ID: 27699

License Grant
Licensor, for itself and its Affiliates, grants to Licensee and its Affiliates in accordance with the terms and conditions of this Agreement, the exclusive right (even as to Licensor and its Affiliates), under all of the existing or future Product Know-How owned or controlled by Licensor or its Affiliates, to register, make or have made, develop, import/export or have imported/exported, use or have used, Market, offer for sale or have sold, and otherwise exploit the Product on a sole and exclusive basis (even as to Licensor and its Affiliates) in or for the Territory.
License Property
The Product 1% testosterone gel AB-rated to AndroGel®; male testosterone gel as an AB-rated equivalent to AndroGel.

AB-rated drugs are drugs that meet the necessary bio-equivalence standards established by the Food and Drug Administration (FDA).

The Licensee will make certain upfront and milestone payments to the company.

The stated royalty rate will increase during the period of time if the Licensee markets the licensed product and is the sole marketer of a generic 1% testosterone gel that is AB-rated to AndroGel® in the United States.

The Licensee is a generic drug manufacturer.

Field of Use
AndroGel® (testosterone gel) 1% and 1.62% are controlled substances, available by prescription, used to treat adult males who have low or no testosterone.

IPSCIO Record ID: 28610

License Grant
The Licensor entered into a License Agreement with the Licensee, granting rights to the Accudel delivery technology to be used for anti-cellulite formulations.
License Property
The Licensor is a specialty pharmaceutical company focused on the commercial development of compounded drug formulations. The Licensor expects to use its proprietary Accudelâ„¢ drug delivery technologies, proprietary drug formulations, and its exclusive relationship with Professional Compounding Centers of America, Inc., to identify pharmaceutical development opportunities where there are significant unmet medical needs.

The Accudelâ„¢ Topical Drug Delivery System is a patented formulation which provides transdermal delivery of high percentage formulations of drugs, both small and large molecules, by a route that avoids first pass metabolism and significant systemic exposure. Accudelâ„¢ contains penetration enhancers which function synergistically to provide for rapid, but controllable transport of an active medication from the Accudel cream onto the skin and into the underlying soft tissue.

Accudelâ„¢ is biodegradable and has low toxicity.  Accudel is made of non-immunogenic components, is thermodynamically stable and is quickly absorbed, as well as being aesthetically pleasing to many.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.